scholarly journals Mst1 regulates non-small cell lung cancer A549 cell apoptosis by inducing mitochondrial damage via ROCK1/F‑actin pathways

2018 ◽  
Author(s):  
Weiqiang Zhang ◽  
Keiqiang Liu ◽  
Yingxin Pei ◽  
Jingbo Ma ◽  
Jiang Tan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
A549 Cell ◽  
Cell Apoptosis ◽  
Mitochondrial Damage ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer A549 Cell

Effect of Umbelliferone on The Proliferation of Non Small Cell Lung Cancer A549 Cell

2020 ◽  
Vol 36 (1) ◽  
pp. 41-46
Author(s):  
Hyeji Han ◽  
◽  
SoonYoung Kwon ◽  
Hyebin Koh ◽  
Nisansala Chandimali ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
A549 Cell ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer A549 Cell

scholarly journals MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin

2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Weili Li ◽  
Wenzhe Wang ◽  
Mingjian Ding ◽  
Xiaoliang Zheng ◽  
Shenglin Ma ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
A549 Cell ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer A549 Cell

scholarly journals Genistein enhances the effect of cisplatin on the inhibition of non-small cell lung cancer A549 cell growth in vitro and in vivo

2014 ◽  
Vol 8 (6) ◽  
pp. 2806-2810 ◽  
Author(s):  
DEZHI LIU ◽  
LING YAN ◽  
LAN WANG ◽  
WEICHENG TAI ◽  
WEILI WANG ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Growth ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
A549 Cell ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer A549 Cell

scholarly journals Midazolam increases cisplatin-sensitivity in non-small cell lung cancer (NSCLC) via the miR-194-5p/HOOK3 axis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Tingting Sun ◽  
Jing Chen ◽  
Xuechao Sun ◽  
Guonian Wang
Keyword(s):  
Lung Cancer ◽  
Cell Proliferation ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cell Apoptosis ◽  
Cisplatin Resistance ◽  
Small Cell ◽  
Luciferase Reporter ◽  
Small Cell Lung ◽  
Cisplatin Sensitivity

Abstract Backgrounds As previously reported, midazolam anesthesia exerts tumor-suppressing effects in non-small cell lung cancer (NSCLC), but the regulating effects of this drug on cisplatin-resistance in NSCLC have not been studied. Thus, we designed this study to investigate this issue and preliminarily delineate the potential molecular mechanisms. Methods We performed MTT assay and trypan blue staining assay to measure cell proliferation and viability. Cell apoptosis was examined by FCM. qRT-PCR and immunoblotting were performed to determine the expression levels of genes. The targeting sites between genes were predicted by bioinformatics analysis and were validated by dual-luciferase reporter gene system assay. Mice tumor-bearing models were established and the tumorigenesis was evaluated by measuring tumor weight and volume. Immunohistochemistry (IHC) was used to examine the pro-proliferative Ki67 protein expressions in mice tumor tissues. Results The cisplatin-resistant NSCLC (CR-NSCLC) cells were treated with high-dose cisplatin (50 μg/ml) and low-dose midazolam (10 μg/ml), and the results showed that midazolam suppressed cell proliferation and viability, and promoted cell apoptosis in cisplatin-treated CR-NSCLC cells. In addition, midazolam enhanced cisplatin-sensitivity in CR-NSCLC cell via modulating the miR-194-5p/hook microtubule-tethering protein 3 (HOOK3) axis. Specifically, midazolam upregulated miR-194-5p, but downregulated HOOK3 in the CR-NSCLC cells, and further results validated that miR-194-5p bound to the 3’ untranslated region (3’UTR) of HOOK3 mRNA for its inhibition. Also, midazolam downregulated HOOK3 in CR-NSCLC cells by upregulating miR-194-5p. Functional experiments validated that both miR-194-5p downregulation and HOOK3 upregulation abrogated the promoting effects of midazolam on cisplatin-sensitivity in CR-NSCLC cells. Conclusions Taken together, this study found that midazolam anesthesia reduced cisplatin-resistance in CR-NSCLC cells by regulating the miR-194-5p/HOOK3 axis, implying that midazolam could be used as adjuvant drug for NSCLC treatment in clinical practices.

Sign in / Sign up

Export Citation Format

Share Document